ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
-0,01%
Bitcoin
63.635,50
1,19%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Rocket Pharmaceuticals Inc (RCKT)

  7. Rocket Pharmaceuticals Inc (RCKT) News

RCKT

Rocket Pharmaceuticals (RCKT)

Rocket Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:RCKT
DatumZeitQuelleÜberschriftSymbolFirma
02/04/202412h00Business WireRocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi AnemiaNASDAQ:RCKTRocket Pharmaceuticals Inc
26/03/202421h01Business WireRocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership TeamNASDAQ:RCKTRocket Pharmaceuticals Inc
05/03/202400h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
05/03/202400h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
29/02/202421h54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
29/02/202420h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
26/02/202422h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RCKTRocket Pharmaceuticals Inc
26/02/202422h01Business WireRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ProgressNASDAQ:RCKTRocket Pharmaceuticals Inc
22/02/202402h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
22/02/202402h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
22/02/202402h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
22/02/202402h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
22/02/202402h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202423h28Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202422h37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202422h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202422h26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
16/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
13/02/202422h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RCKTRocket Pharmaceuticals Inc
13/02/202413h00Business WireRocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)NASDAQ:RCKTRocket Pharmaceuticals Inc
29/01/202421h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RCKTRocket Pharmaceuticals Inc
23/01/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
22/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
22/01/202421h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RCKTRocket Pharmaceuticals Inc
02/01/202422h01Business WireRocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RCKTRocket Pharmaceuticals Inc
13/12/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RCKTRocket Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RCKT

Kürzlich von Ihnen besucht

FX
EURUSD
Euro vs US Dollar
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US100
US Tech 100
PM
XAUUSD
Gold vs US Dollar
NYSE
JPM
JP Morgan Chase
AMEX
XLE
Energy Select Sector SPDR
TG
DBK
Deutsche Bank
TG
BAYN
Bayer
NASDAQ
TSLA
Tesla
NYSE
MCD
McDonalds
NYSE
MRK
Merck
TG
DTE
Deutsche Telekom
TG
BAS
BASF
FX
EURJPY
Euro vs Yen
USOTC
BASFY
BASF (QX)
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten